Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis
Sofie Vaengebjerg, Lone Skov, Alexander Egeberg, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 4, pp. 421-421
Open Access | Times Cited: 174

Showing 26-50 of 174 citing articles:

Integrated bioinformatics combined with machine learning to analyze shared biomarkers and pathways in psoriasis and cervical squamous cell carcinoma
Luyu Liu, Pan Yin, Ruida Yang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
Gerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Rheumatology and Therapy (2021) Vol. 9, Iss. 2, pp. 521-539
Open Access | Times Cited: 37
So close, and yet so far away: The dichotomy of the specific immune response and inflammation in psoriasis and atopic dermatitis
Alexander Schäbitz, Kilian Eyerich, Natalie Garzorz‐Stark
Journal of Internal Medicine (2021) Vol. 290, Iss. 1, pp. 27-39
Open Access | Times Cited: 36
German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations
Alexander Nast, Andreas Altenburg, Matthias Augustin, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2021) Vol. 19, Iss. 7, pp. 1092-1115
Open Access | Times Cited: 34
Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?
Luca Mastorino, Paolo Dapavo, Gianluca Avallone, et al.
Journal of Dermatological Treatment (2021) Vol. 33, Iss. 5, pp. 2495-2502
Closed Access | Times Cited: 33
PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
Ke Zhang, Xiangyi Kong, Yuan Li, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 25
Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study
Cristina Pellegrini, Maria Esposito, Ernesto Rossi, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 11, pp. 2613-2626
Open Access | Times Cited: 24
Transdermal delivery of Fn14 siRNA using a novel composite ionic liquid for treatment of psoriasis-like skin lesions
Lisha Li, Xiying Wu, Junchao Wu, et al.
Journal of Controlled Release (2023) Vol. 365, pp. 818-832
Closed Access | Times Cited: 14
Histone Lactylation Participates in Psoriasis Progression by Regulating the Adiponectin Expression
Sicheng Zhao, Tingyan Wu, Mingjing Fu, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 219-227
Open Access | Times Cited: 6
Causal relationship between several autoimmune diseases and renal malignancies: A two-sample mendelian randomization study
Puyu Liu, Jihang Luo, Lanlan Zhao, et al.
PLoS ONE (2024) Vol. 19, Iss. 2, pp. e0297861-e0297861
Open Access | Times Cited: 5
Autoimmune diseases and female-specific cancer risk: A systematic review and meta-analysis
Simone Fischer, Christa Meisinger, Dennis Freuer
Journal of Autoimmunity (2024) Vol. 144, pp. 103187-103187
Open Access | Times Cited: 5
Cancer risk in patients with psoriasis: should we be paying more attention?
Nikolai Loft, Sofie Vaengebjerg, Lone Skov
Expert Review of Clinical Immunology (2020) Vol. 16, Iss. 5, pp. 479-492
Closed Access | Times Cited: 38
The Risk of Systemic Diseases in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic
Yu Ri Woo, Chul Jong Park, Hoon Kang, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 19, pp. 7041-7041
Open Access | Times Cited: 38
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
Lars Erik Kristensen, Bruce Strober, Denis Poddubnyy, et al.
Therapeutic Advances in Musculoskeletal Disease (2023) Vol. 15
Open Access | Times Cited: 13
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population
Mario Valenti, Giulia Pavia, Luigi Gargiulo, et al.
Journal of Dermatological Treatment (2021) Vol. 33, Iss. 3, pp. 1638-1642
Closed Access | Times Cited: 24
Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study
Veerle Stouten, Sofia Pazmino, Patrick Verschueren, et al.
RMD Open (2021) Vol. 7, Iss. 2, pp. e001671-e001671
Open Access | Times Cited: 24
Decrease in RNase HII and Accumulation of lncRNAs/DNA Hybrids: A Causal Implication in Psoriasis?
Ecmel Mehmetbeyoğlu, Leila Kianmehr, Murat Borlu, et al.
Biomolecules (2022) Vol. 12, Iss. 3, pp. 368-368
Open Access | Times Cited: 18
Skin Inflammation Modulation via TNF-α, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis
Daniel O. Costache, Oana Feroiu, Adelina Ghilencea, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 5198-5198
Open Access | Times Cited: 18
Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure
C.E.M. Griffiths, Melinda Gooderham, Jean‐Frédéric Colombel, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 6, pp. 1431-1446
Open Access | Times Cited: 17
Eosinophilic esophagitis-associated epithelial remodeling may limit esophageal carcinogenesis
Annie D. Fuller, Adam Karami, Mohammad Faujul Kabir, et al.
Frontiers in Allergy (2023) Vol. 4
Open Access | Times Cited: 10
Ankylosing Spondylitis and Cancer Risk
Shiuan‐Tzuen Su, Yung‐Heng Lee, Po‐Cheng Shih, et al.
International Journal of Rheumatic Diseases (2025) Vol. 28, Iss. 1
Closed Access
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials
Joseph F. Merola, Laura K. Ferris, Jeffrey M. Sobell, et al.
Dermatology and Therapy (2025)
Open Access
Risk relationship between six autoimmune diseases and malignancies: An umbrella review
Ping Yang, Qian Liu, Hengheng Zhang, et al.
Autoimmunity Reviews (2025), pp. 103779-103779
Closed Access
Psoriasis and cancer: the role of inflammation, immunosuppression, and cancer treatment
Manfredo Bruni, Fabio Lobefaro, Cristina Pellegrini, et al.
Expert Opinion on Biological Therapy (2025), pp. 1-17
Closed Access
Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials
April W. Armstrong, Mark Lebwohl, Richard B. Warren, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Open Access

Scroll to top